EXEL Exelixis, Inc.
Updated
Healthcare · Biological Products, (No Diagnostic Substances)
Exelixis, Inc. (EXEL) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $14.7 billion. Shares last traded at $59.13, near their 52-week high. Over the past year the stock is up 60.0%. EXEL trades at a price-to-earnings ratio of 17.03, below the Biological Products, (No Diagnostic Substances) median of 22.81. Net profit margin is 35.3%, above the peer median of 5.3%. Revenue grew 7.0% year over year.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-07-03 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $1.60 | 2026-08-05 |
| Q1 2026 | $0.79 | 2026-05-05 |
| FY 2025 | $2.78 | 2026-02-10 |
| Q3 2025 | $1.90 | 2025-11-04 |
| Q2 2026 | $1.20 | 2026-08-05 |
| Q1 2026 | $0.55 | 2026-05-05 |
Biological Products, (No Diagnostic Substances) peers
EXEL vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated
| AMGN | Amgen | $240.1B | 27.47 | 6.30 | 23.0% | +0.31% |
| GILD | Gilead Sciences | $187.5B | -57.87 | 6.16 | -10.6% | +1.09% |
| MRNA | Moderna | $58.8B | -18.68 | — | — | -1.94% |
| RVMD | Revolution Medicines, Inc. | $45.2B | -25.55 | — | — | +0.76% |
| BIIB | Biogen | $33.1B | 24.16 | 3.34 | 13.8% | +0.78% |
| NBIX | Neurocrine Biosciences Inc | $16.1B | 22.81 | 4.77 | 20.9% | +0.33% |
| EXEL | Exelixis, Inc. | $14.7B | 17.03 | 6.02 | 35.3% | +1.00% |
| HALO | Halozyme Therapeutics, Inc. | $12.6B | 30.39 | 7.55 | 24.9% | +1.01% |
| TECH | Bio-Techne | $11.4B | 62.48 | 9.35 | 15.0% | +0.21% |
| KRYS | Krystal Biotech, Inc. | $11.0B | 45.52 | 24.95 | 54.8% | +0.58% |
| APGE | Apogee Therapeutics, Inc. | $10.2B | -34.57 | — | — | +0.04% |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | -32.51 | — | — | -1.24% |
| RGEN | Repligen Corp | $9.6B | 230.53 | 12.20 | 5.3% | -1.87% |
| PCVX | Vaxcyte, Inc. | $9.1B | -8.56 | — | — | -0.62% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.